Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Taro EdahiroTakakazu KawaseHisao NagoshiKeita FujinoKayo ToishigawaTakahiko MiyamaTatsuji MinoTetsumi YoshidaTakehiko MoriokaYuji HirataMitsunori NomaTeruhisa FujiiMasatoshi NishizawaNoriyasu FukushimaTatsuo IchinohePublished in: Hematology (Amsterdam, Netherlands) (2021)
These results suggest that our FBM regimen can be applied to allo-HCT using various graft types and yields acceptable outcomes with relatively low non-relapse mortality in both myeloid and lymphoid neoplasms. Also, we observed a promising survival in the group of patients with high-risk diseases, warranting more accumulation of patients and longer follow-up.
Keyphrases
- bone marrow
- stem cell transplantation
- end stage renal disease
- free survival
- newly diagnosed
- ejection fraction
- high dose
- chronic kidney disease
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- peritoneal dialysis
- dendritic cells
- risk factors
- patient reported outcomes
- acute lymphoblastic leukemia
- cell death
- cell proliferation
- insulin resistance